Translational Modeling of Chloroquine and Hydroxychloroquine Dosimetry in Human Airways for Treating Viral Respiratory Infections

Pulmonary Delivery of Aerosolized Chloroquine and Hydroxychloroquine to Treat COVID-19: In Vitro Experimentation to Human Dosing Predictions

(2022) Aditya R. Kolli et al.   AAPS Journal

Phase 1 Randomized Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate – A Potential Treatment for COVID-19

(2021) Ohad Bentur et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery

(2021) Apoorva Mulay et al.   Cell Reports

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients

(2020) Jianghong Fan et al.   CLINICAL INFECTIOUS DISEASES

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

(2020) Xueting Yao et al.   CLINICAL INFECTIOUS DISEASES

Understanding SARS‐CoV‐2 endocytosis for COVID‐19 drug repurposing

(2020) Oleg O. Glebov   FEBS Journal

Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin

(2020) Hartmut Derendorf   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

(2020) Philippe Gautret et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics

(2020) Andre C. Kalil   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

(2020) Joshua Geleris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19

(2020) Bo Yu et al.   Science China-Life Sciences

Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review

(2020) Anwar M. Hashem et al.   Travel Medicine and Infectious Disease

Dose selection of chloroquine phosphate for treatment of COVID-19 based on a physiologically based pharmacokinetic model

(2020) Cheng Cui et al.   Acta Pharmaceutica Sinica B

Compassionate use of hydroxychloroquine in clinical practice for patients with mild to severe Covid-19 in a French university hospital

(2020) Olivier Paccoud et al.   CLINICAL INFECTIOUS DISEASES

Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling

(2020) Karen Rowland Yeo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy

(2020) Laurel Chandler et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

(2020) David R. Boulware et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis

(2020) Jean-Christophe Lagier et al.   Travel Medicine and Infectious Disease

Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

(2020) Mayla Gabriela Silva Borba et al.   JAMA Network Open

Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants

(2020) Lucy Catteau et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection

(2020) A. Klimke et al.   MEDICAL HYPOTHESES

Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19

(2020) Oisín Kavanagh et al.   MEDICAL HYPOTHESES

β-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway

(2020) Sourish Ghosh et al.   CELL

Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation

(2018) Keagan P. Collins et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells

(2018) Jean Kaoru Millet et al.   VIROLOGY

In Vitro and in Silico Tools To Assess Extent of Cellular Uptake and Lysosomal Sequestration of Respiratory Drugs in Human Alveolar Macrophages

(2017) Ayşe Ufuk et al.   MOLECULAR PHARMACEUTICS

Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity

(2016) Hephzibah Akpovwa   CELL BIOCHEMISTRY AND FUNCTION

Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model

(2015) Stuart D. Dowall et al.   JOURNAL OF GENERAL VIROLOGY

The Endolysosomal System in Cell Death and Survival

(2013) U. Repnik et al.   Cold Spring Harbor Perspectives in Biology

Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial

(2011) Nicholas I Paton et al.   LANCET INFECTIOUS DISEASES

Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn Mice

(2009) E. Keyaerts et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Quantitative modeling of selective lysosomal targeting for drug design

(2008) Stefan Trapp et al.   EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS